' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 32 Researches
7.5
USERS' SCORE
Good
Based on 5 Reviews
8.1
Supplement Facts
Serving Size: 2 Softgels
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%**
Saturated Fat
0.5 g
3%**
Polyunsaturated Fat
1 g
†
Monounsaturated Fat
0.5 g
†
Fish Oil Concentrate
2 g (2,000 mg)
†
Eicosapentaenoic Acid (EPA)
360 mg
†
Docosahexaenoic Acid (DHA)
240 mg
†
Top Medical Research Studies
8
Eicosapentaenoic acid reduces MS symptoms
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Direct evaluation of EPA's effectiveness
We explored the therapeutic effects of eicosapentaenoic acid (EPA) in tackling multiple sclerosis through a study involving mice with experimental autoimmune encephalomyelitis (EAE). The mice were given diets enriched with or without EPA. Remarkably, the mice that received the EPA-infused diet displayed significantly lower clinical scores compared to those that did not.
Furthermore, we observed that the production of inflammatory markers like IFN-γ and IL-17 was notably reduced in the EPA-treated mice. This reduction is particularly important, as these markers are associated with the progression of multiple sclerosis. Additionally, there was an enhancement in the expression levels of peroxisome proliferator-activated receptors within the CD4T cells infiltrating the central nervous system.
These findings suggest that EPA could serve as a promising new approach to therapy for multiple sclerosis, showcasing its potential in reducing inflammation and improving clinical outcomes in those affected by this condition.
Furthermore, we observed that the production of inflammatory markers like IFN-γ and IL-17 was notably reduced in the EPA-treated mice. This reduction is particularly important, as these markers are associated with the progression of multiple sclerosis. Additionally, there was an enhancement in the expression levels of peroxisome proliferator-activated receptors within the CD4T cells infiltrating the central nervous system.
These findings suggest that EPA could serve as a promising new approach to therapy for multiple sclerosis, showcasing its potential in reducing inflammation and improving clinical outcomes in those affected by this condition.
Read More
9
Eicosapentaenoic acid may reduce MS
The effects of omega-3 Fatty acids on matrix metalloproteinase-9 production and cell migration in human immune cells: implications for multiple sclerosis.
Highly relevant to MS inquiry
We explored the effects of eicosapentaenoic acid (EPA), an important omega-3 fatty acid, on multiple sclerosis (MS) by investigating its influence on matrix metalloproteinase-9 (MMP-9) levels and T cell migration. MMP-9 is known to contribute to the disruption of the blood-brain barrier, allowing inflammatory T cells to enter and affect the central nervous system—an essential factor in the progression of MS.
In our study, we used peripheral blood mononuclear cells (PBMC) from healthy individuals, pre-treating them with EPA and another omega-3, docosahexaenoic acid (DHA). We measured the levels and activity of MMP-9 in the cell supernatants. Additionally, we assessed the migration of Jurkat T cells through fibronectin-coated transwells after EPA and DHA treatment. The results were promising; both EPA and DHA notably reduced MMP-9 production and activity, thereby significantly inhibiting human T cell migration.
Our findings suggest that eicosapentaenoic acid could potentially offer therapeutic benefits for MS patients by modulating the immune response and limiting T cell migration that disrupts the blood-brain barrier. This adds to the growing body of evidence supporting the health benefits of omega-3 fatty acids in inflammatory conditions like multiple sclerosis.
In our study, we used peripheral blood mononuclear cells (PBMC) from healthy individuals, pre-treating them with EPA and another omega-3, docosahexaenoic acid (DHA). We measured the levels and activity of MMP-9 in the cell supernatants. Additionally, we assessed the migration of Jurkat T cells through fibronectin-coated transwells after EPA and DHA treatment. The results were promising; both EPA and DHA notably reduced MMP-9 production and activity, thereby significantly inhibiting human T cell migration.
Our findings suggest that eicosapentaenoic acid could potentially offer therapeutic benefits for MS patients by modulating the immune response and limiting T cell migration that disrupts the blood-brain barrier. This adds to the growing body of evidence supporting the health benefits of omega-3 fatty acids in inflammatory conditions like multiple sclerosis.
Read More
9
Pistachio oil shows promise in MS
The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I.
Relevant to MS treatment research
We aimed to evaluate how docosahexaenoic acid, particularly through the treatment of PEGlated nanoliposomes of pistachio unsaturated oils (PEGNLPUOs), affects inflammation in multiple sclerosis (MS).
This investigation was rigorously designed as a randomized, double-blind, placebo-controlled trial, ensuring the reliability of our findings. We observed significant changes in the levels of docosahexaenoic and eicosapentaenoic acid among MS patients treated with PEGNLPUOs.
Moreover, we found a notable decrease in matrix metallopeptidase-9 levels, which is important in regulating inflammation. The cytokine profile showed a tilt towards a Th2-biased response, indicating a reduction in inflammatory activity following treatment.
In summary, our findings indicated a reduction in the number of relapses, improved disability scores, and fewer T2 lesions in patients receiving PEGNLPUOs. Through this study, we demonstrated a promising therapeutic avenue for alleviating inflammation associated with multiple sclerosis using docosahexaenoic acid-based treatments.
This investigation was rigorously designed as a randomized, double-blind, placebo-controlled trial, ensuring the reliability of our findings. We observed significant changes in the levels of docosahexaenoic and eicosapentaenoic acid among MS patients treated with PEGNLPUOs.
Moreover, we found a notable decrease in matrix metallopeptidase-9 levels, which is important in regulating inflammation. The cytokine profile showed a tilt towards a Th2-biased response, indicating a reduction in inflammatory activity following treatment.
In summary, our findings indicated a reduction in the number of relapses, improved disability scores, and fewer T2 lesions in patients receiving PEGNLPUOs. Through this study, we demonstrated a promising therapeutic avenue for alleviating inflammation associated with multiple sclerosis using docosahexaenoic acid-based treatments.
Read More
Most Useful Reviews
9.5
Excellent quality
I've been using this for many years without interruption, despite having multiple sclerosis. The quality is excellent and unmatched by any competitor.
Read More
8
Slowed regression
Omega for health. My wife has multiple sclerosis, and we've been advised to take Omega 3. It’s hard to say how much it has helped, but the progression has slowed down, which is certainly a positive outcome.
Read More
8.8
Helpful supplement
I’ve started taking Omega 3 again, and it’s been helpful for my multiple sclerosis.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 32 Researches
7.5
9
EPA decreases inflammation in MS
Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.
Moderate relevance due to study design
We set out to explore the effects of eicosapentaenoic acid (EPA), a component of fish oil, on individuals with relapsing-remitting multiple sclerosis (MS). In our study, 50 patients received either 4 grams of fish oil daily or a placebo for a full year.
Our primary focus was to measure how this supplementation affected markers of inflammation and oxidative stress, particularly looking at cytokines like TNF α, IL-1 β, and IL-6, as well as nitric oxide levels in the bloodstream.
The results were promising; those taking fish oil showed a significant reduction in these inflammatory markers compared to the placebo group. However, we found no noticeable differences in disability progression or the frequency of relapses among participants.
This suggests that while EPA may help reduce specific inflammatory markers, it doesn’t appear to alter the course of the disease in terms of disability or relapse rates.
Our primary focus was to measure how this supplementation affected markers of inflammation and oxidative stress, particularly looking at cytokines like TNF α, IL-1 β, and IL-6, as well as nitric oxide levels in the bloodstream.
The results were promising; those taking fish oil showed a significant reduction in these inflammatory markers compared to the placebo group. However, we found no noticeable differences in disability progression or the frequency of relapses among participants.
This suggests that while EPA may help reduce specific inflammatory markers, it doesn’t appear to alter the course of the disease in terms of disability or relapse rates.
Read More
9
Eicosapentaenoic acid reduces MS activity
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Relevant but effect hard to isolate
We embarked on a clinical trial to explore whether a specialized formula containing eicosapentaenoic acid could have a positive impact on individuals with relapsing-remitting multiple sclerosis (MS). This study, which lasted 30 months, included 80 participants who were randomly assigned to four groups. Each group either received the active treatment, a variation of it, or a placebo, all while the participants were closely monitored in a double-blind setup to ensure fairness.
We specifically investigated the effectiveness of our new combination of omega-3 and omega-6 fatty acids, alongside vitamins, to gauge its influence on disease activity. The study aimed to evaluate the annualized relapse rate and the progression of disability in these patients. We were pleased to find that the treatment containing eicosapentaenoic acid, known as PLP10, notably reduced the rate of relapses and lower risk of sustained disability progressions without any serious side effects.
While this study paves the way for further exploration, it is essential to acknowledge that larger studies will be necessary to fully understand the long-term safety and effects of eicosapentaenoic acid on MS. Overall, our findings suggest promising potential for eicosapentaenoic acid as a supportive therapy in managing this challenging condition.
We specifically investigated the effectiveness of our new combination of omega-3 and omega-6 fatty acids, alongside vitamins, to gauge its influence on disease activity. The study aimed to evaluate the annualized relapse rate and the progression of disability in these patients. We were pleased to find that the treatment containing eicosapentaenoic acid, known as PLP10, notably reduced the rate of relapses and lower risk of sustained disability progressions without any serious side effects.
While this study paves the way for further exploration, it is essential to acknowledge that larger studies will be necessary to fully understand the long-term safety and effects of eicosapentaenoic acid on MS. Overall, our findings suggest promising potential for eicosapentaenoic acid as a supportive therapy in managing this challenging condition.
Read More
9
Eicosapentaenoic acid may reduce MS
The effects of omega-3 Fatty acids on matrix metalloproteinase-9 production and cell migration in human immune cells: implications for multiple sclerosis.
Highly relevant to MS inquiry
We explored the effects of eicosapentaenoic acid (EPA), an important omega-3 fatty acid, on multiple sclerosis (MS) by investigating its influence on matrix metalloproteinase-9 (MMP-9) levels and T cell migration. MMP-9 is known to contribute to the disruption of the blood-brain barrier, allowing inflammatory T cells to enter and affect the central nervous system—an essential factor in the progression of MS.
In our study, we used peripheral blood mononuclear cells (PBMC) from healthy individuals, pre-treating them with EPA and another omega-3, docosahexaenoic acid (DHA). We measured the levels and activity of MMP-9 in the cell supernatants. Additionally, we assessed the migration of Jurkat T cells through fibronectin-coated transwells after EPA and DHA treatment. The results were promising; both EPA and DHA notably reduced MMP-9 production and activity, thereby significantly inhibiting human T cell migration.
Our findings suggest that eicosapentaenoic acid could potentially offer therapeutic benefits for MS patients by modulating the immune response and limiting T cell migration that disrupts the blood-brain barrier. This adds to the growing body of evidence supporting the health benefits of omega-3 fatty acids in inflammatory conditions like multiple sclerosis.
In our study, we used peripheral blood mononuclear cells (PBMC) from healthy individuals, pre-treating them with EPA and another omega-3, docosahexaenoic acid (DHA). We measured the levels and activity of MMP-9 in the cell supernatants. Additionally, we assessed the migration of Jurkat T cells through fibronectin-coated transwells after EPA and DHA treatment. The results were promising; both EPA and DHA notably reduced MMP-9 production and activity, thereby significantly inhibiting human T cell migration.
Our findings suggest that eicosapentaenoic acid could potentially offer therapeutic benefits for MS patients by modulating the immune response and limiting T cell migration that disrupts the blood-brain barrier. This adds to the growing body of evidence supporting the health benefits of omega-3 fatty acids in inflammatory conditions like multiple sclerosis.
Read More
9
Pistachio oil shows promise in MS
The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I.
Relevant to MS treatment research
We aimed to evaluate how docosahexaenoic acid, particularly through the treatment of PEGlated nanoliposomes of pistachio unsaturated oils (PEGNLPUOs), affects inflammation in multiple sclerosis (MS).
This investigation was rigorously designed as a randomized, double-blind, placebo-controlled trial, ensuring the reliability of our findings. We observed significant changes in the levels of docosahexaenoic and eicosapentaenoic acid among MS patients treated with PEGNLPUOs.
Moreover, we found a notable decrease in matrix metallopeptidase-9 levels, which is important in regulating inflammation. The cytokine profile showed a tilt towards a Th2-biased response, indicating a reduction in inflammatory activity following treatment.
In summary, our findings indicated a reduction in the number of relapses, improved disability scores, and fewer T2 lesions in patients receiving PEGNLPUOs. Through this study, we demonstrated a promising therapeutic avenue for alleviating inflammation associated with multiple sclerosis using docosahexaenoic acid-based treatments.
This investigation was rigorously designed as a randomized, double-blind, placebo-controlled trial, ensuring the reliability of our findings. We observed significant changes in the levels of docosahexaenoic and eicosapentaenoic acid among MS patients treated with PEGNLPUOs.
Moreover, we found a notable decrease in matrix metallopeptidase-9 levels, which is important in regulating inflammation. The cytokine profile showed a tilt towards a Th2-biased response, indicating a reduction in inflammatory activity following treatment.
In summary, our findings indicated a reduction in the number of relapses, improved disability scores, and fewer T2 lesions in patients receiving PEGNLPUOs. Through this study, we demonstrated a promising therapeutic avenue for alleviating inflammation associated with multiple sclerosis using docosahexaenoic acid-based treatments.
Read More
9
DHA's impact on multiple sclerosis
A Novel Combination of Docosahexaenoic Acid, All-Trans Retinoic Acid, and 1, 25-Dihydroxyvitamin D Reduces T-Bet Gene Expression, Serum Interferon Gamma, and Clinical Scores but Promotes PPARγ Gene Expression in Experimental Autoimmune Encephalomyelitis.
Combination therapy complicates isolation
We aimed to understand how docosahexaenoic acid (DHA) influences multiple sclerosis by exploring its effects in combination with other nutrients. Through a carefully designed study, we assessed the protective benefits of DHA, alongside all-trans retinoic acid (ATRA) and 1,25-dihydroxyvitamin D, on a model of multiple sclerosis known as experimental autoimmune encephalomyelitis (EAE).
The study involved female C57BL/6 mice divided into treated and untreated groups to observe the impact of these nutrients on the disease's progression. The results were striking. We found that when DHA was administered with ATRA and vitamin D, there was a significant reduction in clinical symptoms, and less interferon gamma and T-bet gene expression—key contributors to the inflammatory response observed in multiple sclerosis.
While the combination treatment showed clear benefits, it's important to note that the specific role of DHA on its own was difficult to isolate. The intervention collectively reduced the severity of the disease and inflammation, hinting at its potential for treating similar autoimmune conditions. Overall, our findings suggest that exploring DHA within combined therapies might be a promising pathway for managing multiple sclerosis.
The study involved female C57BL/6 mice divided into treated and untreated groups to observe the impact of these nutrients on the disease's progression. The results were striking. We found that when DHA was administered with ATRA and vitamin D, there was a significant reduction in clinical symptoms, and less interferon gamma and T-bet gene expression—key contributors to the inflammatory response observed in multiple sclerosis.
While the combination treatment showed clear benefits, it's important to note that the specific role of DHA on its own was difficult to isolate. The intervention collectively reduced the severity of the disease and inflammation, hinting at its potential for treating similar autoimmune conditions. Overall, our findings suggest that exploring DHA within combined therapies might be a promising pathway for managing multiple sclerosis.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.1
9.5
Excellent quality
I've been using this for many years without interruption, despite having multiple sclerosis. The quality is excellent and unmatched by any competitor.
8.8
Helpful supplement
I’ve started taking Omega 3 again, and it’s been helpful for my multiple sclerosis.
8
Slowed regression
Omega for health. My wife has multiple sclerosis, and we've been advised to take Omega 3. It’s hard to say how much it has helped, but the progression has slowed down, which is certainly a positive outcome.
7
Preventive measure
I use this high-quality product as a preventative measure against multiple sclerosis. It contains guaranteed ingredients, is suitable for all ages, and has a pleasant taste.
3.8
Beneficial effects
Okiga 3. O God, may this medicine be beneficial to our bodies and without harm. The packaging is secure, and it’s gentle on the stomach, containing antioxidants and multiple minerals. The quantity is adequate with no taste.
